Bone Health

Treatment of multiple myeloma with bortezomib (Velcade) results in an overall gain in bone formation, according to a computer-assisted image analysis of bone marrow core biopsies conducted at the University of Utah, Salt Lake City.

Multiple myeloma (MM) is the most common cancer that involves the skeleton, with >80% of patients developing bone lesions.1 Complications resulting from bone destruction in myeloma are largely responsible for quality-of-life limitations as well as poor performance status.1 The National Comprehensive Cancer Network (NCCN) lists the intravenous (IV) bisphosphonates zoledronic acid and pamidronate as category 1 level recommendations for all patients receiving primary myeloma therapy.2 Additional NCCN recommendations for the treatment of myelomarelated bone d

Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology